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Abstract

Data driven conclusion is mostly accepted approach in any medical research problem. In case of limited knowledge of deep idea about supportive data on the problem, automatic digging of the variable plays important role for insight view of
the study. Bayesian model averaging can be considered for automatics variable
selection. It can be used as an alternative of stepwise regression method. The
aim of this paper is to show the application of Bayesian modeling averaging in
medical research particularly in cancer trial. Method is illustrated on Bone marrow transplant data. It can be recommended that BMA can be used frequently in
data selection and as a tool of exploratory data analysis method. It is very handy
method of choice for data analysis.
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regression method. The aim of this paper is to show the application of Bayesian modeling
averaging in medical research particularly in cancer trial. Method is illustrated on Bone marrow
transplant data. It can be recommended that BMA can be used frequently in data selection and as
a tool of exploratory data analysis method. It is very handy method of choice for data analysis.
Keywords:- Prior, Posterior , Bayesian Information Criteria and Decision Information Criteria.

1
Hosted by The Berkeley Electronic Press

Bayesian Model Averaging:- An Application in Cancer Clinical Trial
In case of limited subject matter information, automatic variable selection is
useful to explore relation between outcome and covariates. Although, logistic regression
and stepwise selection are general approach to be considered to explored the relation
between outcome and covariates. But it is tedious and time consuming. But the resulting
estimates is depends on the choice of the selected model. The particular selected model
can leads to the significance or insignificance test result. In addition, selected regression
model do not show the uncertainty about choice of the assumed model in the Statistical
Interpretation.
Bayesian methods in clinical trial and in medical research have become pretty
well-known in last ten years due to flexible application, easy interpretation, good
operative features. Bayesian is more useful in longitudinal, survival and clinical drug
treatment comparison. It is performed quite well in adaptive trial design.
In model selection it can also be useful and can be choice as automatic model
selection. Bayesian Modeling Averaging (BMA)

givs the lack of confidence in a

canonical regression. Let y be the dependents variable,  a constant,  , the coefficients,
and  a normal IID having variance   .
  





, ~ 0,   .

(1)

Based on primary end point of the study it is easy to define Y. But among several , it is not
possible to select best X. The problem in variable selection is X not Y.
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BMA attempts the problem through estimating the models among all probable combination of
  and gives the information about weighted average of all of them. Let X is represented as
,

,

 and

.

Then possible models are 2  16.

In experimental study, K numbers of variables may be considered. The number of possible
model would be 2 . But, selection of best model among 2 models is very difficult. BA with
weighted average solve the problem.
Modeling
Let the Model  , prefers the covariates

.

Then by Bayes theorem it

can be presented as

 /,  

!"#/$% &!$% 

("#/$% ,'&!$% 

!#/'

∑*,-. ("#/$% ,'&!$% 

=

+

(2)

Now, the likelihood of /  for the particular data set will not change. Then it
can be stated that 0"/ , & is the proportional to the marginal likelihood of 0"/
 ,  time prior probability  . The term 0"/ , & is the posterior model
probability of the data given model.
Let the coefficient() in equation (1) is estimated by 1 . Then
+
1 /2,   ∑34 "1 / , , &" / , &.

(3)

Here, s is the possible set of all models. The prior probability models i.e.   5 1 to gives the
minimum effect of knowledge.
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Acceptance of BMA
In classical approach,   0.05 is well accepted principle in the scientific
community. BMA can be used in this manner. A 95% threshold value can be applied for
posterior estimation. In this stydy, 95% posterior threshold is used for selecting best
predictor. The analysis is performed to compare the performance of linear regression
selection step and BMA. The well-know and widely, applied method in stepwise
regression is found poorly performed in the theory and case –studies [ Raftery et al.,
1997 and Malek et al.,2007].
Data Methodology
The graft dataset comes from a non-depleted allogeneic bone marrow transplant
from an HLA-identical sibling donor for a haematological malignancy of 37 patients in
GvHD trial. Information was recorded on recipient age, donor age, type of leukemia and
status of pregnancy. The aim of the work by Bagot et al,. [1988] was to detect the
donor/recipient pairs at high risk of GvHD who might benefit of bone marrow T-cell
depletion. The basic characteristics of the data are provided into the Table 1 and Table
respectively.

Bayesian Model
Bayesian methodology in statistical Inference is well-documented [Gelman et a.,
2004, Carlin and Louis 2008 and Ibrahim et al., 2001]. Bayesian differs from the
classical in terms f uncertainty of the unknown parameter in a model is expressed through
an entire distribution called the prior distribution. The term “prior” expressed the
4
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uncertainty of the parameters before collecting the data in the study. The main inferential
tool is possible through posterior distribution by application of Bayes Theorem. If 71 
be the prior information about parameter . 89:;:/1  is the likelihood function of the
data given the parameter . Then 7/9:;:∞89:;:/7 is posterior distribution
of parameter. The major consideration in the Bayesian is the selection of prior. Priors that
have a minimal influence on the overall Bayesian analysis are called non-informative
prior. Flat, Vague, reference-priors are synonyms of the non-informatrive prior. The
result obtained through non-informative prior is very much similar with classical
approach. The non-informative prior is relatively “flat” towards distribution of the data.
Bayesian con be computed in WinBugs, SAS and R. These software packages are
very powerful for data analysis. Markov Chain Monte Carlo(MCMC) is only required to
performed to obtain the Bayesian results. Softwares are now a day’s compatible for
Bayesian computation. MCMC is basically simulation based approach to draw sample
from the posterior distribution of  and have already established as powerful tool for
even complex model. Dealing with Complex model is really infeasible for classical
method.
Illustration of BMA
The ‘graft data’ data set describe above having 8 variables named with
“gvhd“,“index”, “dead”,“preg”, “rcpage “,“time“,“type“ and “donage “respectively. The
“rcpage” is considered as outcome of interest and rest all are covariates. Now, as stated
earlier a total of 28 types of model can be formed. Here, BMS library in R software is
used. R is open source software and can be downloaded from www.cran-project.org. In
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the bms function, prior is defined as “uniform”. The results obtained through bms
function on response variables are listed in Table 3.
In the above results, post mean provides the information about averaged over all
model in particular coefficient. It shows that variable “gvhd” has the highest coefficient
value in comparison to others. The posterior inclusion criterion gives the importance of
the variable in the data. It can be noted that the PIP value and post mean are positively
correlated. Only “gvhd” can be considered as an important variable in comparison to
others. The posterior standard deviation gives more information: “gvhd” is positively
influencing to the on response , but “rcpage” worked as negatively. The column named
with “Index” gives the indices value of the variable in the data set.
Modeling
The posterior model size can be obtained by sum of all PIP. In this example, it
comes around 3.60.As stated earlier, MCMC is useful for simulation techniques. The
correlation between analytical observation of PMP and iteration is given in figure1. It
shows that correlation between iteration and analytical observation are in decent level.A
total of 2000 models are genereated. The best filled 50 models are given in figure 2.The
relative performance for consideration of uniform, Fixed, PIP and random prior are given
in Figure2.
Discussion

There are several procedures to detect the best fitted models. The procedures are
Bayesian Information Criteria (BIC)[ Neath and Cavanaugh (2012)], Decision
Information

Criteria

[Spiegelhalter

et

al.,

(2002)]

and

Akkai

Information
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Criteria[Burnham et al. (2002)]. However, the application of those approaches only
becomes useful when parameters are selected. In case of presence of crude or unselected
parameters, none of the approach can be performed well. The application of BMA is very
simple. The open source software R can be used to perform the BMA[Ref]. More detailed
application of BMA through R are recently discussed [Clyde (2010), Raftery et al.
(2010a) and Feldkircher and Zeugner (2011)].

Conclusion
The BMA is useful to explore the prior information about the prior distribution of
the parameter of interest. It is useful to specify the parameters to be considered in model
development stage. The stabilize prediction can only be obtained through application of
BMA. An application of BMA on “graft data” set is presented. The Bayesian analysis
on graft data is applied for the model illustration. It is suggested to specify about BMA in
the protocol itself to develop the track for further model development in study design.
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Table1: graft dataset summary of continuous variable
Parameters

Mean

sd

Parameters

Mean

Sd

Rcpage

25.43

7.50

Donage

25.81

7.83

Time

669.8

483.71

Index

2.55

2.22

Freq(%)

Table2: graft dataset summary of categorical variable
Parameters

Status

Freq(%)

Parameters

Status

Donor

Yes

10(27.02%)

Type

Acute

Pregnancy

myoloid 11(29.72%)

leukarmia(AML)

Status

No

27(72.98%)

Acute

Dead

Yes

19(51.35%)

lymphocytic

16(43.24%)

leukarmia(ALL)
No

Chronic myeloid 10(27.02%)

18 (48.64)

leukarmia(CML)
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Table 3:- The coefficient table covariates on response variable.
Parameters
gvhd

PIP
1.0000000

Post Mean

Post SD

Cond.Pos.Sign

Index

12.9443355327 1.5636948959

1.0000000

6

index

0.9999999

2.2755190644

0.3000631051

1.0000000

5

dead

0.4607726

-1.0737612621

1.4614983330

0.0000000

8

preg

0.4302314

1.0833786240

1.5705677172

1.0000000

4

rcpage

0.2063585

0.0173867110

0.0541033943

1.0000000

1

time

0.1992714

0.0002177483

0.0009393523

0.8183941

7

type

0.1549690

0.0106012518

0.3709706438

0.4850185

3

donage

0.1504394

-0.0039444487

0.0358654882

0.1477814

2
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Figure1:- The correlation between PMP and iterations.
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Figure2:- The best fitted models
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